Market Overview

Alector Announces $133 Million in Series E Financing to Advance Broad Portfolio of Immuno-Neurology and Immuno-Oncology Programs


First three programs to focus on Alzheimer's disease and
frontotemporal dementia

Alector, a privately held biotechnology company focused on developing
therapies that harness the immune system to cure neurodegenerative
diseases and cancer, today announced the closing of a $133
million Series E financing. The proceeds from the financing will be used
to advance Alector's clinical programs and expand the company's
discovery platform.

Deerfield Management, AbbVie Ventures, Federated Kaufmann Fund, Section
32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures, New Leaf
Venture Partners, Perceptive Advisors, Casdin Capital, Polaris Partners,
OrbiMed, MRL Ventures, GV, the Dementia Discovery Fund, Mission Bay
Capital, Amgen Ventures, and others participated in the financing.

"There has been a lack of new approaches to treat the underlying causes
of devastating neurodegenerative diseases such as frontotemporal
dementia (FTD) and Alzheimer's disease," said Sabah Oney, Ph.D., chief
business officer of Alector. "At Alector, we are focused on the
advancement of innovative, first-in-class medicines to treat these
serious diseases. We are thrilled to have strong support from
industry-leading investors, and this financing ensures sufficient
resources for the continued development of our novel drug pipeline."

Recent human genetic studies indicate that the development of
neurodegenerative diseases is due in part to a dysfunctional immune
system in the brain. Alector is developing immuno-neurology drugs that
harness the brain's immune system to counteract multiple pathologies at
the same time. "We anticipate that empowering a patient's own immune
system could provide as much benefit for patients suffering from
neurodegeneration as immuno-oncology therapies have demonstrated for
cancer patients," said Arnon Rosenthal, Ph.D., Alector's chief executive

Guided by these emerging studies, especially with regards to the
inherited risk of Alzheimer's disease, Alector has identified a
portfolio of drug candidates that the company believes have the
potential to restore normal immune function to the aging brain and
counteract neurodegeneration. Today, Alector announced the intended
indications for its first three neurodegenerative disease drug

  • AL001 is being developed for the treatment of FTD. Mutations in
    AL001's target protein are known to be causal for FTD.
  • AL002 targets a triggering receptor expressed on myeloid cells 2
    (TREM2), which is known to contribute to the development and
    progression of Alzheimer's disease and other neurodegenerative
  • AL003 targets SIGLEC-3, a transmembrane receptor expressed on cells of
    myeloid lineage, which is a known prevalent risk factor for
    Alzheimer's disease.

"There are currently no FDA-approved treatments that can make a direct
impact on the progression of Alzheimer's disease or FTD," said Thomas C.
Südhof, M.D., Ph.D., professor at the Stanford University School of
Medicine and the recipient of the Nobel Prize in Physiology or Medicine
in 2013. According to Dr. Südhof, an incoming member of Alector's
Scientific Advisory Board, "bold, new ideas are imperative to address
these significant patient populations that are in great need of
treatment options."

"At Alector, our focus is on integrating emerging knowledge in human
genetics, immunology, neuroscience, oncology, and large data analytics
to treat neurodegenerative diseases and cancer. This strategy is paying
off with a broad portfolio of programs and strong investor support,"
said Dr. Rosenthal.

About Alector, Inc.

Alector is a privately held biotechnology company focused on developing
therapies that harness the immune system to cure neurodegenerative
diseases and cancer. Founded by thought leaders in biotechnology,
neuroscience, and antibody drug discovery, Alector is headquartered in
South San Francisco, California. For more information, please visit

View Comments and Join the Discussion!